Авторы

  • Azizov B.S., Nurmatova I.B.
  • Xusnitdinova D.M.

Ключевые слова:

o‘rta yoshdagi ayollar, katta yoshdagi ayollar aknesi, androgenlar, IGF-1, mTORC1, Cutibacterium acnes, spironolakton, topikal retinoidlar, davolash algoritmi.

Библиографические ссылки

1. Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris // Scientific Reports. — 2020. — Vol. 10. — Art. 5754. — DOI: 10.1038/s41598-020-62715-3.

2. Bagatin E., Freitas T.H.P., Rivitti-Machado M.C. et al. Adult female acne: a guide to clinical practice // Anais Brasileiros de Dermatologia. — 2019. — Vol. 94, No. 1. — P. 62–75. — DOI: 10.1590/abd 1806-4841.20198203.

3. Amuzescu A., Tampa M., Matei C., Georgescu S.R. Adult Female Acne: Recent Advances in Pathophysiology and Therapeutic Approaches // Cosmetics. — 2024. — Vol. 11, No. 3. — Art. 74. — DOI: 10.3390/cosmetics11030074.

4. Telkkälä A., Sinikumpu S.-P., Huilaja L. Etiology of Adult Female Acne: Systematic Review // Health Science Reports. — 2025. — Vol. 8, No. 5. — Art. e70697. — DOI: 10.1002/hsr2.70697.

5. Cong T.-X., Hao D., Wen X. et al. From pathogenesis of acne vulgaris to anti-acne agents // Archives of Dermatological Research. — 2019. — Vol. 311, No. 5. — P. 337–349. — DOI: 10.1007/s00403-019-01908-x.

6. Lee Y.B., Byun E.J., Kim H.S. Potential Role of the Microbiome in Acne: A Comprehensive Review // Journal of Clinical Medicine. — 2019. — Vol. 8, No. 7. — Art. 987. — DOI: 10.3390/jcm8070987.

7. Melnik B.C. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne // Experimental Dermatology. — 2013. — Vol. 22, No. 5. — P. 311–315. — DOI: 10.1111/exd. 12142.

8. Meixiong J., Ricco C., Vasavda C., Ho B.K. Diet and acne: A systematic review // JAAD International. — 2022. — Vol. 7. — P. 95–112. — DOI: 10. 1016/j.jdin.2022.02.012.

9. Teede H.J., Tay C.T., Laven J.J.E. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome // European Journal of Endocrinology. — 2023. — Vol. 189, No. 2. — P. G43–G64. — DOI: 10.1093/ejendo/lvad096.

10. Layton A.M., Bettoli V., Delore V. et al. The Burden of Acne Vulgaris on Health-Related Quality of Life and Psychosocial Well-Being Domains: A Systematic Review // American Journal of Clinical Dermatology. — 2026. — Vol. 27. — P. 17–47. — DOI: 10. 1007/s40257-025-00983-3.

11. Reynolds R.V., Yeung H., Cheng C.E. et al. Guidelines of care for the management of acne vulgaris // Journal of the American Academy of Dermatology. — 2024. — Vol. 90, No. 5. — P. 1006.e1–1006.e30. — DOI: 10.1016/j.jaad.2023.12.017.

12. Hebert A., Thiboutot D., Stein Gold L. et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials // JAMA Dermatology. — 2020. — Vol. 156, No. 6. — P. 621–630. — DOI: 10.1001/jamadermatol.2020.0465.

13. Santer M., Lawrence M., Renz S. et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial // BMJ. — 2023. — Vol. 381. — Art. e074349. — DOI: 10.1136/bmj-2022-074349.

14. Plovanich M., Weng Q.Y., Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne // JAMA Dermatology. — 2015. — Vol. 151, No. 9. — P. 941–944. — DOI: 10.1001/jamadermatol.2015.34.